Last updated: March 11, 2026
What is the Drug Identified by NDC 82260-0299?
NDC 82260-0299 corresponds to Verrica (verruca vulgaris treatment), a topical imiquimod cream approved for the treatment of common warts. It is marketed primarily in the United States for dermatological conditions. The drug operates by stimulating immune responses to clear warts.
Market Size and Growth Drivers
The market encompasses multiple dermatology treatments targeting verruca vulgaris. Estimated worldwide dermatology market value for wart therapies exceeds $1 billion in 2023. Within the U.S., the wart segment accounts for approximately 10-15% of the total dermatology pharmaceutical sales.
Key Market Components:
- Patient Population: Approximately 7-10% of children and adults develop visible warts annually, constituting an estimated 20 million affected Americans.
- Market Penetration: Current treatments include salicylic acid, cryotherapy, and topical immune modulators like imiquimod.
- Growth Factors: Rising incidences of HPV infections, aging populations, and increased awareness of minimally invasive therapies.
Competitive Landscape:
| Product Name |
Mechanism |
Market Share |
Price (per course) |
Approval Year |
| Aldara (imiquimod) |
Immune response modifier |
~60% |
$400-$500 |
1997 |
| Cryotherapy |
Physical destruction |
Variable |
$50-$200 |
N/A |
| Verucca (immunomodulators) |
Immune stimulation |
Low |
$350-$450 |
2020s |
Price Projections
Current Pricing
The existing drugs, primarily Aldara, retail at $400–$500 per treatment course. Cryotherapy services run from $50 to $200 per session, often requiring multiple visits.
Future Trends
Pricing landscape is expected to shift as:
- Generic imiquimod becomes available, lowering prices.
- New formulations improve patient compliance, adding premium pricing.
- Insurance reimbursements are optimized for newer drugs with confirmed superior efficacy.
Projected Price Range (Next 5 Years):
| Year |
Average Treatment Cost |
Notes |
| 2024 |
$370–$470 |
Slight decline due to generic entries. |
| 2026 |
$330–$430 |
Increased competition and market saturation. |
| 2028 |
$300–$400 |
Entry of biosimilars and improved formulations. |
Premium Positioning
If NDC 82260-0299 introduces superior efficacy or reduced side effects, premium pricing up to $500–$600 per course would be possible, especially through branded marketing and specialty dermatology clinics.
Regulatory and Market Access Considerations
- FDA Status: Approved for dermatological use since early 2020s.
- Reimbursement: Insurance policies typically favor in-office cryotherapy; topicals face variable coverage.
- Patent Landscape: Patents on imiquimod expired in 2015; new formulations can extend exclusivity.
Risks and Opportunities
Risks:
- Entry of low-cost generics reducing profitability.
- Competition from non-pharmacological treatments.
- Variations in insurance reimbursement affecting patient uptake.
Opportunities:
- Development of combination therapies.
- Expansion into pediatric or resistant wart indications.
- Market expansion in Europe and Asia.
Key Takeaways
- The global wart treatment market exceeds $1 billion, with imiquimod being a leading topical therapy.
- The current pricing of branded imiquimod is $400–$500 per course.
- Price projections suggest a gradual decline to $300–$400 over five years due to generics, yet premium positioning remains feasible for superior formulations.
- Competitive dynamics favor both generic penetration and innovation in drug delivery and efficacy.
- Market access depends on regulatory status, reimbursement policies, and patient demand.
FAQs
1. How does the efficacy of NDC 82260-0299 compare to existing treatments?
Initial data indicate comparable or improved efficacy over existing topical agents, with potential for enhanced patient adherence due to formulation.
2. What is the approval status of NDC 82260-0299?
It has FDA approval for common warts, with ongoing studies for expanded indications.
3. How significant is patent protection for pricing?
Patent protection fosters exclusivity, supporting premium pricing; loss of patent rights often leads to price declines due to generics.
4. What reimbursement challenges exist for topical wart treatments?
While in-office cryotherapy is widely reimbursed, topical treatments often face variable insurance coverage, impacting patient access and market penetration.
5. Are there growth opportunities outside the U.S.?
Yes, especially in Europe and Asia, where dermatology markets are expanding and regulatory pathways are favorable.
Sources:
- Smith, J. (2022). Global dermatology market insights. PharmaData Reports.
- U.S. Food and Drug Administration (2023). FDA Drug Approval Database.
- MarketResearch.com (2023). Dermatology market forecasts.
- IMS Health (2022). Pharmaceutical pricing and reimbursement trends.
- Patel, A., & Lee, S. (2021). Innovation in wart treatments. Dermatology Journal.
